Abstract Details

Title TRH Administered by Mouth Inhibits Acute EAE

Topic MS and Related Diseases

Presentation(s) P05 - (-)

Poster/Presentation
Number 168

Objective

Background BACKGROUND: Ingested immunoactive proteins type I IFN, SIRS peptide 1-21, ?-MSH, ACTH, SST and NPY inhibit clinical attacks and inflammation in acute EAE by decreasing Th1-like cytokines, increasing Th2-like cytokines or increasing Treg cell frequencies.

Design/Methods DESIGN/METHODS: B6 mice were immunized with MOG peptide 35-55 and gavaged with control saline, 10-100 mcg TRH starting on day 17 post immunization during ongoing disease. Splenocytes from mock or active treatment mice were adoptively transferred into actively immunized mice. H&E stained cord sections were evaluated for inflammation by a blinded observer.

Results RESULTS: Ingested (oral) TRH inhibited ongoing disease and decreased inflammation. Adoptively transferred cells from TRH fed donors protected against actively induced disease and decreased inflammation. In actively fed mice, oral TRH decreased IL-17 and TNF-? cytokines in both the spleen and the CNS. In recipients of donor cells from TRH fed mice there was a reduction of Th1 and Th17 and induction of Th2-like IL-13 cytokines in both the spleen and CNS. Oral TRH decreased clinical score and decreased inflammatory foci in both actively fed and recipients of actively fed mice. There was no significant increase in Treg cell frequencies in actively fed or recipients of TRH fed donor cells.

Conclusions CONCLUSIONS: Ingested (orally administered) TRH can inhibit clinical disease, inhibit CNS inflammation by decreasing Th1-like, Th17 and TNF-? cytokines and increasing Th2-like cytokines (IL-13) in the CNS.

Authors/Disclosures
Staley A. Brod, MD (Staley Brod, MD) PRESENTER	Dr. Brod has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Brod has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi.
	No disclosure on file
Sian D. Spacey, MD, MBBS (Dr. Sian Spacey Inc)	Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for abbvie. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartits. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for lilly. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for abbvie. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for lilly. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for lundbeck. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for abbvie. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for lilly.
Charles Yonan, PharmD (Avanir Pharmaceuticals)	No disclosure on file

��ɫ��

��ɫ��